Can-Fite BioPharma Shifts Drug Manufacturing to China

Published: Jan 22, 2013

by Richard Daverman, PhD

January 21, 2013 -- Can-Fite Biopharma, an Israeli firm developing drugs for inflammatory and liver disease, will transfer its drug production to China. The company said China’s Chemspec has optimized production of its APIs, reducing its costs considerably. Can-Fite is facing multiple Phase III clinical trials for its drug candidates, and it estimates that outsourcing the manufacturing to Chemspec will save the company millions of dollars. More details....

Stock Symbols: (TASE: CFBI; OTCBB: CANFY)

Back to news